BROWSE

Related Scientist

Kim, Ho Min's photo.

Kim, Ho Min
단백질 커뮤니케이션 그룹
more info

ITEM VIEW & DOWNLOAD

Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy

Cited 0 time in webofscience Cited 0 time in scopus
31 Viewed 0 Downloaded
Title
Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy
Author(s)
Jang, Seil; Song, Jaeho; Kim, NaYoung; Bak, Jeonghyeon; Jung, Keehoon; Park, Young Woo; Park, Bum-Chan; Kim, Ho Min
Publication Date
2021-04
Journal
BIOMATERIALS, v.271
Publisher
ELSEVIER SCI LTD
Abstract
Following the clinical success of immunotherapeutic antibodies, bispecific antibodies for cytotoxic effector cell redirection, tumor-targeted immunomodulation and dual immunomodulation, have received particular attentions. Here, we developed a novel bispecific antibody platform, termed Antibody-Like Cell Engager (ALiCE), wherein the Fc domain of each heavy chain of immunoglobulin G (IgG) is replaced by the VH and VL domains of an IgG specific to a second antigen while retaining the N-terminal Fab of the parent antibody. Because of specific interactions between the substituted VH and VL domains, the C-terminal stem Fv enables ALiCE to assemble autonomously into hetero-tetramers, thus simultaneously binding to two distinct antigens but with different avidities. This design strategy was used to generate ACE-05 (two anti-PD-L1 Fab ? anti-CD3 Fv) and ACE-31 (two anti-CD3 Fab ? anti-PD-L1 Fv), both of which bound PD-L1 and CD3. However, ACE-05 was more effective than ACE-31 in reducing off-target toxicity caused by the indiscriminate activation of T cells. Moreover, in cell-based assays and PBMC-reconstituted humanized mice harboring human non-small-cell lung cancer tumors, ACE-05 showed marked antitumor efficacy, causing complete tumor regression at a dose of 0.05 mg/kg body weight. The dual roles of ACE-05 in immune checkpoint inhibition and T-cell redirection, coupled with reduced off-target toxicity, suggest that ACE-05 may be a promising anti-cancer therapeutic agent. Moreover, the bispecific ALiCE platform can be further used for tumor-targeted or multiple immunomodulation applications.
URI
https://pr.ibs.re.kr/handle/8788114/9560
DOI
10.1016/j.biomaterials.2021.120760
ISSN
0142-9612
Appears in Collections:
Pioneer Research Center for Biomolecular and Cellular Structure(바이오분자 및 세포구조 연구단) > Protein Communication Group(단백질 커뮤니케이션 그룹) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse